Poor
Not Aligned
Patient Risk:
High
Summary
Only the IL-17A monoclonal antibody mechanism is supported by the provided label excerpts (12.1). Most other claims cannot be confirmed because critical label sections (Indications 1 and Dosage/Administration 2) are not included, and no provided excerpts support the majority of safety, dosing, and adverse-reaction statements.
Category Scores
Accurate Statements
Cosentyx is a monoclonal antibody that targets interleukin-17A (IL-17A).
Supported by 12.1 (secukinumab selectively binds IL-17A).
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication.
Not explicitly supported by the provided label excerpts.
Cosentyx is used to treat psoriasis.
Indications/usage section text (section 1) is not provided (shown as <text/>), so approval cannot be verified.
Cosentyx is used to treat psoriatic arthritis.
Indications/usage section text (section 1) is not provided, so approval cannot be verified.
Cosentyx is used to treat ankylosing spondylitis.
Indications/usage section text (section 1) is not provided, so approval cannot be verified.
By blocking IL-17A, Cosentyx reduces inflammation.
12.1 supports inhibition of IL-17A interaction and inhibition of release of proinflammatory mediators, but the specific claim wording 'reduces inflammation' is not explicitly stated in the provided excerpt.
Cosentyx is administered via injection.
Injection administration is only indirectly supported via subcutaneous injection technique counseling; the claim is not fully supported as written by the provided excerpts.
Cosentyx is typically administered every four weeks.
Dosage frequency information (section 2) is not included in the provided excerpts.
Patients taking Cosentyx were more likely to experience falls compared to those taking a placebo.
No provided label excerpt contains fall/imbalance comparisons.
The increased risk of falls with Cosentyx may be related to the medication's effect on the central nervous system.
No provided label excerpt links falls to central nervous system effects.
Cosentyx can increase the risk of osteoporosis.
No provided label excerpt mentions osteoporosis risk.
The risk of falls is a significant concern with Cosentyx because it can increase the risk of osteoporosis.
No provided label excerpt supports either falls as a labeled concern or an osteoporosis link.
Patients taking Cosentyx had a higher risk of osteoporosis-related fractures compared to those taking a placebo.
No provided label excerpt mentions osteoporosis-related fractures or placebo comparisons.
Cosentyx can cause dizziness.
No provided label excerpt mentions dizziness as an adverse effect.
Dizziness and vertigo can increase the risk of falls in some patients taking Cosentyx.
No provided label excerpt supports dizziness/vertigo or any relationship to falls.
Cosentyx can cause vertigo.
No provided label excerpt mentions vertigo.
Cosentyx can cause fatigue.
No provided label excerpt supports fatigue as an adverse reaction.
Fatigue can impair balance and increase the risk of falls.
No provided label excerpt supports a fatigue-to-balance-to-falls relationship.
Cosentyx has been associated with neurological side effects such as seizures and tremors.
No provided label excerpt mentions seizures/tremors or neurological adverse effects.
Neurological side effects such as seizures and tremors can increase the risk of falls.
No provided label excerpt links neurological adverse effects to falls.
Cosentyx can increase the risk of osteoporosis, particularly in patients with a history of osteoporosis.
No provided label excerpt mentions osteoporosis or risk stratification by history.
Cosentyx can increase the risk of osteoporosis, particularly in patients taking corticosteroids.
No provided label excerpt mentions osteoporosis risk or corticosteroid-related risk modification.
Common side effects of Cosentyx include injection site reactions.
The provided excerpts do not list common side effects or specify injection site reactions.
Common side effects of Cosentyx include upper respiratory tract infections.
Provided excerpts list 'Infections' as a category but do not specify upper respiratory tract infections as common.
Common side effects of Cosentyx include fatigue.
The provided excerpts do not list fatigue.
Contradictions
Important Omissions
Boxed warnings and detailed warnings/precautions content (sections 5 and any boxed warning section) were not assessable from the provided excerpts, despite multiple safety-related claims being made (falls/osteoporosis/dizziness/vertigo/neuro effects).
Importance:
High
Dosage/administration details (section 2) were not provided, yet a dosing frequency claim ('every four weeks') was made.
Importance:
High
Indications and usage details (section 1) were not provided, yet multiple indications (psoriasis, psoriatic arthritis, ankylosing spondylitis) were claimed.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Multiple safety and risk claims (falls, osteoporosis/fractures, dizziness/vertigo, fatigue, neurological effects) are not supported by the provided label excerpts and cannot be verified from the provided prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most extracted claims are unsupported or unverifiable because key label sections (1 and 2) and detailed safety sections were not provided in the prompt.
Suggested Improvement
Limit claims to label-supported content from the provided excerpts (e.g., 12.1 mechanism). Provide the full FDA label text for sections 1, 2, 5, and 6 before evaluating or asserting specific indications, dosing frequency, and adverse reactions.